Member news

Cotton Mouton Diagnostics (CMD), a cutting-edge UK-based diagnostics technology company, has received a half-a-million-pound investment from CPI Enterprises as part of the Innovate UK Catapult Investment Pilot.

Brainomix, a global leader in AI-powered imaging solutions in stroke and lung fibrosis, has announced the appointment of Anna Griffin as Chief Financial Officer, filling a key leadership role within the company following its recent £14 million Series C funding round.

Rosalind brings extensive leadership experience across the health and life sciences sector. She has led the Government’s Office for Life Sciences for the last four years, bringing together the Government, the NHS, academia and industry to drive improved patient outcomes and economic growth through life sciences.

LIfT BioSciences ('LIfT' or 'the Company')today announces a grant of €12 million has been awarded from Ireland's Disruptive Technologies Innovation Fund

Members of the Industry Skills Accelerator (ISA) have celebrated a successful year of strengthening the UK’s medicines manufacturing workforce.

CGT Catapult, an independent technology and innovation organisation specialising in the advancement of the cell and gene therapy industry, has appointed Dr Jim Faulkner as its new Chairman, effective from 29th July 2025.

The UK government has officially launched its landmark Life Sciences Sector Plan, backed by over £2 billion in public funding and spearheaded by the Department for Science, Innovation and Technology, Business and Trade, and Health and Social Care.

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at A$439 million.

The Milner Therapeutics Institute is delighted to be featured in a new report celebrating a decade of partnership and impact between AstraZeneca and the University of Cambridge.

Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organisation specialising in the advancement of the cell and gene therapy industry, has appointed Dr Ed Samuel as its Chief Operations Officer (COO).

Pioneer Group and Science Creates today announce a new partnership that will support the next generation of science and technology ventures across the UK and Ireland.

Logical Biological, biospecimen and critical material experts, today announced the launch of a new sister company, Logical Antigen, focused on rapid and customised delivery of high-quality antigens and biologicals, for research and manufacturing of diagnostic products.

PIR International recently partnered with Sibylla Biotech in appointing Dieter Weinand as Non-Executive Chair.

Construction of Europe’s tallest and most technically sophisticated purpose-built commercial lab building has started on site at Canary Wharf, London.

The pioneering gene therapy company is consolidating its UK office and lab space to form a central innovation hub at 20 Water Street.

A response from Discovery Park’s CEO, Mayer Schreiber, in light of the Government’s Life Science Sector Plan.

Myricx Bio announces that it has been awarded the Cancer Research Horizons Start-Up Achievement Recognition Award for 2025, which it received at a ceremony in London last night.

Cellular Origins, the Cell and Gene Therapy Catapult and Resolution Therapeutics today announce the formation of a consortium which has been awarded a cross-industry Smart Grant of £1 million from Innovate UK, the UK’s national innovation agency.

Coulter Partners successfully completed a search assignment for QBiotics Group Limited (QBiotics) and announces the placement of Sergio Duchini as Non-executive Director.

PIR International spoke with the Chief Executive Officer of Muna Therapeutics, Rita Balice-Gordon, as part of their BioLeader interview series.